A Retrospective Study Assessing the Safety of Anti-Fibrotic Therapy in the Peri-Transplant Period in Idiopathic Pulmonary Fibrosis Patients from Australia and New Zealand Cardiothoracic Organ Transplant Registry (ANZCOTR).
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 26 Apr 2018 New trial record
- 14 Apr 2018 Preliminary results (n=43; to date) assessing anastomotic outcomes in idiopathic pulmonary fibrosis patients receiving anti-fibrotic therapy (pirfenidone and nintedanib) in the peri-transplant period, presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.